Skip to content
Screener

PP&E (Net) at other companies

Schrodinger logo
SchrodingerSDGR
$19.46M-10.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$89.62M-25.3%
Celcuity logo
CelcuityCELC
$619K+72.9%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$34.61M+4.7%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.4M-6.5%
Immunome logo
ImmunomeIMNM
$17.08M+55.9%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemJune 30, 2026December 31, 2025
Prepaid expenses8,73517,787
Other current assets8,4135,974
Total current assets928,082578,279
Property and equipment, net8621,726
Operating lease assets37,17739,990
Restricted cash1,3361,336
Total assets$967,457$621,331
Liabilities and Stockholders’ Equity

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s PP&E (net)?
Relay Therapeutics, Inc. (RLAY) reported PP&E (net) of $862K in Q2 2026.
How has Relay Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Relay Therapeutics, Inc.'s PP&E (net) decreased by 75.1% year-over-year, from $3.46M to $862K.
What is the long-term trend for Relay Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s PP&E (net) has grown at a -22.7% compound annual growth rate (CAGR), from $6.25M to $1.73M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Relay Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude